Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors

Neuroendocrinology

Volumn 99, Issue 2, 2014, Pages 63-74

  Toumpanakis, Christos ^a   Kim, Michelle K ^b   Rinke, Anja ^c   Bergestuen, Deidi S ^d   Thirlwell, Christina ^a   Khan, Mohid S ^a   Salazar, Ramon ^e   Oberg, Kjell ^f  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Gastroenteropancreatic neuroendocrine tumors; Molecular imaging; Positron emission tomography; Somatostatin receptor scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 5 HYDROXYTRYPTOPHAN; 6 FLUORODOPA F 18; CARBON 11; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAXETAN GA 68; UNCLASSIFIED DRUG; FLUORINE 18; FLUORODEOXYGLUCOSE; GLUCAGON LIKE PEPTIDE 1; TETRAXETAN; (3 IODOBENZYL)GUANIDINE;

ARTICLE; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; META ANALYSIS; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCINTIGRAPHY; TREATMENT RESPONSE; TUMOR LOCALIZATION; CANCER LOCALIZATION; CANCER SIZE; COMPUTER ASSISTED TOMOGRAPHY; GASTROINTESTINAL TRACT SCINTISCANNING; HEALTH SURVEY; META ANALYSIS (TOPIC); METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; DIGESTIVE SYSTEM NEOPLASMS; ECHOGRAPHY; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROCEDURES; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS;

3-IODOBENZYLGUANIDINE; DIGESTIVE SYSTEM NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; INTESTINAL NEOPLASMS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; QUESTIONNAIRES; RADIONUCLIDE IMAGING; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 84905024052     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000358727     Document Type: Article

References (44)

1. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet 1998; 352: 799-805.
2. Reubi JC, Laissue J, Waser B, Horisberger U, Schaer JC: Expression of somatostatin receptors in normal, inflammed and neoplastic human gastrointestinal tissues. Ann NY Acad Sci 1994; 733: 122-137.
3. Rindi G, Arnold R, Bosman FT, et al: Nomenclature and classification of neuroendocrine neoplasms of the digestive system; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours in the Digestive System, ed 4. Lyon, IARC, 2010, pp 13-14.
4. Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruszniewski P, Ahlman H, Wiedenmann B; European Neuroendocrine Tumor Society: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. A consensus statement on behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology 2004; 80: 394-424.
5. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K, Watkinson A: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors. Gut 2005; 54 (suppl 4):1-16.
6. Sundin A, Garske U, Orlefors H: Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 69-85.
7. Centre for Evidence Based Medicine. Levels of Evidence. http://www.cebm.net/index.aspx?o.1025 (accessed June 2011).
8. de Herder WW, Lamberts SW: Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14: 53-57.
9. Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Hojgaard L, Kjaer A: Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123 IMIBG scintigraphy, and 18 F-FDG PET. J Nucl Med 2010; 51: 704-712.
10. Oberg K, Castellano D: Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 2011; 30 (suppl 1):3-7.
11. Abgral R, Leboulleux S, Deandreis D, Auperin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E: Performance of (18)fluorodeoxyglucose- positron emission tomography and somatostatin receptor scintigraphy for high Ki67 ( ≥ 10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011; 96: 665-671.
12. Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G, Mignon M, Bourguet P, Le Guludec D: Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111 In-pentetreotide scintigraphy. J Nucl Med 2002; 43: 889-895.
13. Shah T, Kulakiene I, Quigley AM, Warbey VS, Srirajaskanthan R, Toumpanakis C, Hochhauser D, Buscombe J, Caplin ME: The role of 99m Tc-depreotide in the management of neuroendocrine tumors. Nucl Med Commun 2008; 29: 436-440.
14. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ: 99m Tc-HYNIC-[Tyr3]- octreotide for imaging somatostatin-receptor- positive tumors: preclinical evaluation and comparison with 111 In-octreotide. J Nucl Med 2000; 41: 1114-1119.
15. Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R: An intrapatient comparison of 99m Tc-EDDA/HYNIC-TOC with 111 In-DTPoctreotide for diagnosis of somatostatin receptor- expressing tumors. J Nucl Med 2003; 44: 708-716.
16. Cwikla JB, Mikolajczak R, Pawlak D, Buscombe JR, Nasierowska-Guttmejer A, Bator A, Maecke HR, Walecki J: Initial direct comparison of 99m Tc-TOC and 99m Tc-TATE in identifying sites of disease in patients with proven GEP NETS. J Nucl Med 2008; 49: 1060-1065.
17. Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 2004; 151: 15-27.
18. 177Lu- DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 881-888.
19. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A: 18 F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16: 978-985.
20. Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, Langstrom B, Oberg K, Eriksson B: Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol 1998; 16: 2534-2541.
21. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, Brouwers AH, Jager PL, de Vries EG: Improved staging of patients with carcinoid and islet cell tumors with 18 F-dihydroxy-phenyl-alanine and 11 C- 5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008 20; 26: 1489-1495.
22. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, Di Pierro D, Ferrari M, Marengo M, Bergamini C: 68 Ga- DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med 2008; 35: 72-79.
23. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, Maecke H: Are radiogalliumlabelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med 2007; 34: 982-993.
24. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V: Diagnostic performance of gallium- 68 somatostatin receptor PET and PET/ CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta- analysis. Endocrine 2012; 42: 80-87.
25. Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, Tshori S, Glaser B, Bocher M, Salmon A, Chisin R, Gross DJ, Freedman N: Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med 2012; 37: 57-62.
26. Ambrosini V, Campana D, Tomassetti P, Grassetto G, Rubello D, Fanti S: PET/CT with 68 Gallium-DOTA-peptides in NET: an overview. Eur J Radiol 2011; 80:e116-e119.
27. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ: High management impact of Ga- 68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol 2012; 56: 40-47.
28. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ: Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga- DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18 F-FDG. Cancer 2008; 112: 2447-2455.
29. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S: Comparison between 68 Ga-DOTA-NOC and 18 F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008; 35: 1431-1438.
30. Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S: (68) Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010; 37: 722-727.
31. Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, Uslu I, Kanmaz B: Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012; 39: 1271-1277.
32. Gotthardt M, Behe MP, Grass J, Bauhofer A, Rinke A, Schipper ML, Kalinowski M, Arnold R, Oyen WJ, Behr TM: Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumors. Endocr Relat Cancer 2006; 13: 1203-1211.
33. Brom M, Joosten L, Laverman P, Oyen WJ, Behe M, Gotthardt M, Boerman OC: Preclinical evaluation of 68 Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors. Mol Imaging 2011; 10: 144-152.
34. Wild D, Macke H, Christ E, Gloor B, Reubi JC: Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008; 359: 766-768.
35. Christ E, Wild D, Forrer F, Brandle M, Sahli R, Clerici T, et al: Glucagon-like peptide 1-receptor imaging for localization of insulinomas. J Clin Endocrinol Metab. 2009; 94: 4398-4405.
36. Wild D, Christ E, Caplin ME, Kurzawinski TR, Forrer F, Brandle M, Seufert J, Weber WA, Bomanji J, Perren A, Ell PJ, Reubi JC: Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011; 52: 1073-1078.
37. Sowa-Staszczak A, Pach D, Miko?ajczak R, Macke H, et al: Glucagon-like peptide-1 receptor imaging with [Lys 40 (Ahx-HYNIC- 99m Tc/EDDA)NH 2 ]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 2013; 40: 524-531.
38. Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, et al: [Lys40 (Ahx- DTPA-111In) NH2]-exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor targeted therapy for insulinoma. Clin Cancer Res 2007; 13: 3696-3705.
39. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J: The role of 68 Ga- DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111 In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51: 875-882.
40. Savelli G, Lucignani G, Seregni E, Marchiano A, Serafini G, Aliberti G, Villano C, Maccauro M, Bombardieri E: Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun 2004; 25: 445-449.
41. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP: Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010; 37: 67-77.
42. Ambrosini V, Campana D, Nanni C, Cambioli S, Tomassetti P, Rubello D, Fanti S: Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? Eur J Nucl Med Mol Imaging 2012; 39: 1278-1283.
43. Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959.
44. Desai K, Watkins J, Woodward N, Quigley AM, Toumpanakis C, Bomanji J, Caplin M: Use of molecular imaging to differentiate liver metastasis of colorectal cancer metastasis from neuroendocrine tumor origin. J Clin Gastroenterol 2011; 45:e8-e11.